Core Viewpoint - JunTai Holdings (00630.HK) announced the resignation of independent non-executive director Ye Mengmei, effective from October 2, 2025, due to her desire to allocate more time to other matters [1] Company Summary - Ye Mengmei will resign from her position as an independent non-executive director and as a member of the company's remuneration committee, nomination committee, and audit committee [1]

Core Viewpoint - JunTai Holdings (00630) announced the resignation of Ms. Ye Mengmei as an independent non-executive director and member of the company's remuneration committee, nomination committee, and audit committee, effective from October 2, 2025 [1] Group 1 - Ms. Ye Mengmei is resigning to allocate more time to other matters [1]

（於百慕達註冊成立之有限公司） （股份代號：630） 董事名單與其角色和職能 雋泰控股有限公司董事會（「董事會」）成員載列如下： 執行董事： 賈明暉先生 （主席） 張亨鑫先生 獨立非執行董事： 歐陽銘賢先生 郭鎮輝先生 董事會設立3個委員會，各委員會成員載列如下： 審核委員會： 歐陽銘賢先生 （主席） 郭鎮輝先生 薪酬委員會： 香港，二零二五年十月二日 歐陽銘賢先生 （主席） 張亨鑫先生 提名委員會： 張亨鑫先生 （主席） 郭鎮輝先生 * 僅供識別 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 （於百慕達註冊成立之有限公司） （股份代號：630） 獨立非執行董事辭任 雋泰控股有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣佈，葉夢美女 士（「葉女士」）因希望投放更多時間於其他事務而提呈辭任獨立非執行董事以及 本公司薪酬委員會、提名委員會及審核委員會各自之成員，自2025年10月2日起生 效。 葉女士已確認，彼與董事會並無意見分歧，亦無有關彼辭任之其他事宜須提請香 港聯合交易所有限公司（「聯交所」）或本公司股東垂注。 於葉女士辭任後，本公司僅有兩名獨立非執行董事，而獨立非執行董事的人數以 及本公司審核委員會、提名及薪酬委員會各自的成員人數低於聯交所證券上市規 則（「上市規則」）第3.10(1)條、第3.21條及第3.25條規定的人數。 賈明暉 香港，2025年10月2日 於本公告日期，執行董事為張亨鑫先生及賈明暉先生；而獨立非執行董事為歐陽 銘賢先生及郭鎮輝先生。 雋泰控股有限公司 * ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: AMCO United Holding Limited 呈交日期: 2025年9月30日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00630 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 8,000,000,000 | HKD | | 0.05 | HKD | | 400,000,000 | | 增加 / 減少 (-) | | | 0 | | | | HKD | | | | 本月底結存 | | | 8,000,000,000 | HKD | | 0.05 | HKD | ...

謹此通知 閣下，雋泰控股有限公司*（「本公司」）之下述公司通訊2（「本次公司通訊」）之中、英文版本，現已登 載於本公司網站www.amco-united.com（「本公司網站」）及香港聯合交易所有限公司（「聯交所」）網站 www.hkexnews.hk（「聯交所網站」）以供閱覽： • 2025中期報告 請於本公司網站「投資者關係」一欄或聯交所網站內讀取本次公司通訊。若閣下早前曾要求收取公司通訊的印刷本，本 次公司通訊的印刷本已隨函附上。 為了支援通過電郵進行電子通訊，建議非登記股東向代其持有股份的銀行、經紀、託管商或代理人（統稱「中介機構」） 提供其有效的電郵地址。如 本公司沒有收到 閣下的中介機構透過香港中央結算（代理人）有限公司提供 閣下的有效的 電郵地址或郵寄地址，本公司將不會向閣下發送登載通知。 若 閣下希望收取本次公司通訊及/或日後公司通訊之印刷版本，請填隨附之申請表格並交回本公司的香港股份過戶登記 分處（「香港股份過戶登記分處」）卓佳證券登記有限公司，地址為香港夏慤道16號遠東金融中心17樓或發送電子郵件 至is-ecom@vistra.com。請注意，非登記股東收取日後公司通訊的印刷版本要求將直 ...

（於百慕達註冊成立之有限公司） （股份代號：630） 各位登記股東： 於本公司網站登載公司通訊之通知 2025年9月30日 附件 謹此通知 閣下，雋泰控股有限公司*（「本公司」）之下述公司通訊1（「本次公司通訊」）之中、英文版本，現已 登載於本公司網站www.amco-united.com（「本公司網站」）及香港聯合交易所有限公司（「聯交所」）網站 www.hkexnews.hk（「聯交所網站」）以供閱覽： • 2025中期報告 請於本公司網站「投資者關係」一欄或聯交所網站內讀取本次公司通訊。若閣下早前曾要求收取公司通訊的印刷本， 本次公司通訊的印刷本已隨函附上。 為了支援通過電郵進行電子通訊，本公司建議 閣下向本公司香港股份過戶登記分處卓佳證券登記有限公司（「香港 股份過戶登記分處」）（地址為香港夏慤道16號遠東金融中心17樓）發出（不少於7天的）合理書面通知，或發送電 郵至is-ecom@vistra.com向本公司提供 閣下的電郵地址。 股東有責任提供有效的電郵地址。若 閣下沒有提供有效的電郵地址，本公司將透過郵寄方式向 閣下發送 (i) 於本 公司網站登載公司通訊之通知函，以及(ii) 所有日後可供採 ...

Revenue and Profitability - For the six months ended June 30, 2025, the Group's revenue increased by HK$5.1 million or 23.2% to HK$27.1 million compared to HK$22.0 million in the same period last year, primarily driven by the Medical Products Business[4]. - Gross profit rose by HK$1.6 million or 23.5% to HK$8.4 million, with a slight increase in gross profit margin to 30.9% from 30.8% in the previous year[5]. - Overall profit attributable to owners of the Company was HK$1.1 million, a recovery from a loss of HK$25.4 million in the same period last year[11]. - Profit before income tax for the period was HK$1,148,000, a significant recovery from a loss of HK$25,429,000 in the prior year[82]. - Reportable segment profit before income tax for the six months ended June 30, 2025, was HK$5,437,000, a significant recovery from a loss of HK$21,889,000 in 2024[116]. Medical Products Business - The Medical Products Business generated revenue of HK$22.1 million, an increase of HK$5.8 million from HK$16.3 million, accounting for 81.3% of the Group's total revenue[12]. - The segment profit for the Medical Products Business was HK$3.3 million, up from HK$1.7 million in the prior year, reflecting effective cost control and resource utilization strategies[15]. - Revenue from external customers for the Medical Devices Business was HK$22,080,000 for the six months ended 30 June 2025, compared to HK$16,327,000 for the same period in 2024, representing a growth of 35.5%[107][109]. - The reportable segment profit for the Medical Devices Business was HK$3,288,000 for the six months ended 30 June 2025, compared to HK$1,688,000 for the same period in 2024, reflecting an increase of 94.8%[107][109]. Securities Investment - The Group recorded a net unrealised and realised gain of HK$3.4 million from Securities Investment, a significant turnaround from a loss of HK$22.9 million in the previous year[20]. - The Group recorded a net unrealized and realized gain of HK$3.4 million from trading investments for the six months ended June 30, 2025, compared to a loss of HK$22.9 million for the same period in 2024[22]. - The Securities Investment segment generated a profit of HK$3,445,000 in the first half of 2025, compared to a loss of HK$22,897,000 in the same period of 2024, indicating a significant turnaround[107][109]. Financial Position - As of June 30, 2025, the Group's consolidated net asset increased to approximately HK$61.3 million, up from HK$60.1 million as of December 31, 2024[33]. - The Group's total cash and bank balances increased to approximately HK$6.2 million as of June 30, 2025, compared to HK$4.6 million as of December 31, 2024[35]. - The Group had zero borrowings from financial institutions as of June 30, 2025, maintaining a debt-free status[35]. - The Group's total liabilities increased to HK$86,429,000 as of June 30, 2025, from HK$68,302,000 as of December 31, 2024[148]. - The Group's total reportable segment assets as of June 30, 2025, amounted to HK$179,841,000, a decrease from HK$129,265,000 as of June 30, 2024[114]. Cash Flow and Liquidity - Net cash generated from operating activities was HK$504,000, compared to a cash outflow of HK$3,358,000 in the same period last year[87]. - The Group aims to maintain liquidity by effectively managing working capital and controlling costs in response to economic uncertainties[29]. - The Group's current ratio as of June 30, 2025, was 2.1, down from 2.3 as of December 31, 2024[40][45]. Expenses and Costs - Distribution costs increased by HK$0.3 million to HK$2.5 million, while administrative expenses rose by HK$0.5 million or 8.5% to HK$6.4 million[10]. - Staff costs for the six months ended June 30, 2025, were HK$1,617,000, up from HK$1,477,000 in 2024[123]. Share Capital and Dividends - The Board of Directors did not recommend the payment of an interim dividend for the six months ended June 30, 2025, similar to the situation in the previous year[44][49]. - The Group's issued and fully paid share capital remained at HK$48,378,000 as of June 30, 2025, unchanged from December 31, 2024[156]. Corporate Governance - The Company has complied with all code provisions of the Corporate Governance Code for the six months ended June 30, 2025[74]. - The audit committee reviewed the unaudited interim results for the six months ended June 30, 2025, ensuring compliance with accounting principles[79]. Employee Information - The Group had 30 employees as of June 30, 2025, consistent with the number as of December 31, 2024[43][48]. - The remuneration of key management personnel for the six months ended June 30, 2025, was HK$426,000, up from HK$408,000 for the same period in 2024[159].

致：香港交易及結算所有限公司 公司名稱: AMCO United Holding Limited 呈交日期: 2025年9月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00630 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 8,000,000,000 | HKD | | 0.05 | HKD | | 400,000,000 | | 增加 / 減少 (-) | | | 0 | | | | HKD | | | | 本月底結存 | | | 8,000,000,000 | HKD | | 0.05 | HKD | | 400,000,000 | 本月底法定/註冊股本總額： HKD 400,000,000 FF301 第 1 頁 共 10 頁 v ...

Core Viewpoint - JunTai Holdings (00630.HK) reported a revenue of HKD 27.1 million for the six months ending June 30, 2025, representing a year-on-year increase of 23.2% primarily driven by increased revenue from its medical products business [1] Financial Performance - The company achieved a profit attributable to owners of HKD 1.1 million, a turnaround from a loss of HKD 25.4 million in the same period of 2024 [1] - Earnings per share were reported at HKD 0.12 cents [1]